口服藥物治療子宮頸癌前病變？

Using Oral Drug for the Therapy of Cervical Dysplasia

李耀泰(Yiu-Tai Li) ； 朱益志(Yi-Chih Chu) ； 陳福民(Fu-Min Chen) ； 沈仁達(Jenta Shen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2010年2期 (2010/10) Pp. 7-11

https://doi.org/10.7010/JGO.201010.0007

摘要

許多研究認為抑制環氧化酶(cyclooxygenase-2, COX-2)有致癌性質，它會產生細胞增殖、分裂、細胞沾黏、自然凋亡(apotosis)、免疫反應、和血管增生等，使癌細胞加速生長。在人類子宮頸癌前病變，常有COX-2高度顯示，而且病灶有顯示(expression)患者有較高復發比例。口服COX-2抑制劑乃一種非類固醇抗消炎劑，可以選擇抑制COX-2，但可避免胃腸副作用，現可能認為作為治療癌症治療藥物。最近，celecoxib（COX-2抑制劑）被證明可能治療子宮頸癌前病變，甚至能作為癌症預防藥物。

關鍵字

抑制環氧化酶－2 COX-2 ； 子宮頸癌前病變

並列摘要

Several studies suggest that cyclooxygenase-2 (COX-2) is important in carcinogenesis, it may play a role in cancer progression by affecting cell proliferation, mitosis, cell adhesion, apoptosis, immune surveillance, and angiogenesis. Initial studies in human cervix demonstrate that higher expression of COX-2 in cervical intraepithelial neoplasia (CIN) at surgical excision is associated an increased rate of recurrence. COX-2 inhibitor are a class of non-steroidal anti-inflammatory drugs (NSAIDs) selective for the COX-2 enzyme, whereby significant upper gastrointestinal toxicity is averted when administered orally, making it an attractive potential chemotherapeutic agent. Recent, celecoxib (COX-2 inhibitor) has shown potential as a medical treatment for cervical pre-invasive disease. Future studies into the inhibition of COX-2 when treating pre-invasive disease may play a much larger role on cancer prevention.

並列關鍵字

cyclooxygenase-2 COX-2 ； cervical dysplasia ； cervical intraepithelial neoplasia CIN